

KACIAN DANIEL L  
Form 4  
January 06, 2010

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KACIAN DANIEL L

(Last) (First) (Middle)

GEN-PROBE  
INCORPORATED, 10210  
GENETIC CENTER DRIVE

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
GEN PROBE INC [GPRO]

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/04/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
Exec. VP, Chief Scientist

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                                      |
| Common Stock                    | 01/04/2010                           |  | M                              |   | 24,251  | A  | \$ 12.29                                   |
| Common Stock                    | 01/04/2010                           |  | M                              |   | 36,749  | A  | \$ 13.655                                  |
| Common Stock                    | 01/04/2010                           |  | M                              |   | 70,000  | A  | \$ 29.525                                  |
| Common Stock                    | 01/04/2010                           |  | S <sup>(1)</sup>               |   | 88,928  | A  | \$ 43.0136                                 |
|                                 |                                      |  |                                |   |   |  | <sup>(2)</sup>                             |

Edgar Filing: KACIAN DANIEL L - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (Right to Buy)                | \$ 12.29   | 01/04/2010                           |  | M                              | 9,544   | <u>(3)</u> 09/01/2011                                    | Common Stock  | 9,544                         |
| Stock Option (Right to Buy)                | \$ 12.29   | 01/04/2010                           |  | M                              | 14,707  | <u>(4)</u> 06/01/2012                                    | Common Stock  | 14,707                        |
| Stock Option (Right to Buy)                | \$ 13.655  | 01/04/2010                           |  | M                              | 36,749  | <u>(5)</u> 08/17/2010                                    | Common Stock  | 36,749                        |
| Stock Option (Right to Buy)                | \$ 29.525  | 01/04/2010                           |  | M                              | 70,000  | <u>(6)</u> 08/15/2013                                    | Common Stock  | 70,000                        |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                           |       |
|--|---------------|-----------|---------------------------|-------|
|  | Director      | 10% Owner | Officer                   | Other |
| KACIAN DANIEL L<br>GEN-PROBE INCORPORATED<br>10210 GENETIC CENTER DRIVE<br>SAN DIEGO, CA 92121 |               |           | Exec. VP, Chief Scientist |       |

## Signatures

/s/ R. William Bowen,  
Attorney-in-Fact

01/06/2010

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise of options to purchase an aggregate of 88,928 shares of common stock of the issuer and the sale of such shares of common stock were in each case effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2009.  
This transaction was executed in multiple trades at prices ranging from \$42.78 to \$43.26. The price reported above reflects the weighted average sale price for these transactions. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the reported transactions were effected.
- (2) The stock option became fully vested and exercisable as of September 1, 2005.
- (3) The stock option became fully vested and exercisable as of June 1, 2006.
- (4) The stock option became fully vested and exercisable as of August 17, 2004.
- (5) The stock option became fully vested and exercisable as of August 15, 2007.
- (6) The stock option became fully vested and exercisable as of August 15, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.